Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LSP1 CRISPR/Cas9 KO Plasmid (h): sc-406808
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LSP1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LSP1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LSP1 Antibody (TDP153): sc-53363
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LSP1 CRISPR/Cas9 KO Plasmid (h) | sc-406808 | 20 µg | $397.00 |
Overview
Lymphocyte-specific protein 1 (LSP1) is an F-actin–binding cytoskeletal regulator enriched in leukocytes and endothelial cells that coordinates cell shape, motility, and adhesion. It functions in signaling networks downstream of immune receptors and chemokine cues, influencing integrin-dependent trafficking, transendothelial migration, and spatial organization of actin remodeling at the cell cortex. Through these roles, LSP1 contributes to leukocyte activation dynamics, antigen-presenting cell behavior, and vascular barrier interactions. Dysregulated LSP1 expression or function has been linked to altered inflammatory responses and immune-cell migration phenotypes relevant to immunopathology and hematologic disease biology.
LSP1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LSP1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LSP1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LSP1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LSP1 protein expression.
This CRISPR knockout system enables efficient generation of LSP1-deficient cell models for investigation of LSP1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting LSP1 exon(s) critical for LSP1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple LSP1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LSP1 CRISPR/Cas9 KO Plasmid (h) and LSP1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LSP1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LSP1 HDR Plasmid (h) and LSP1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LSP1 homology arms to support homology-directed repair at defined LSP1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.